Bimekizumab shows sustained MRI and radiographic benefits in axial spondyloarthritis

Pooled MRI and radiographic data from the phase 3 BE MOBILE 1 and 2 trials and their open-label extension evaluated bimekizumab, a dual IL-17A/IL-17F inhibitor, in patients with non-radiographic and radiographic axial spondyloarthritis. The study reported substantial reductions in SIJ and spine inflammation scores at Week 52, decreased erosion scores, increased backfill and fat lesion scores, minimal ankylosis change, and minimal radiographic progression through Week 104 with continued bimekizumab treatment.

Most relevant for: Patients with non-radiographic or radiographic axial spondyloarthritis being considered for or continuing IL-17 inhibitor therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.